XBiotech (XBIT)
(Delayed Data from NSDQ)
$8.81 USD
+0.25 (2.92%)
Updated May 14, 2024 04:00 PM ET
After-Market: $8.81 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for XBiotech Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 4 | 18 | 44 | 0 |
Cost Of Goods | 0 | 1 | 6 | 35 | 0 |
Gross Profit | 0 | 3 | 13 | 9 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 38 | 38 | 38 | 28 | 31 |
Income After Depreciation & Amortization | -38 | -34 | -25 | -18 | -31 |
Non-Operating Income | 13 | 1 | 0 | 5 | 750 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -24 | -34 | -25 | -13 | 718 |
Income Taxes | 0 | -1 | -8 | -2 | 50 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -25 | -33 | -17 | -11 | 669 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -25 | -33 | -17 | -11 | 669 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -36 | -32 | -22 | -16 | -29 |
Depreciation & Amortization (Cash Flow) | 2 | 3 | 3 | 2 | 2 |
Income After Depreciation & Amortization | -38 | -34 | -25 | -18 | -31 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 30.44 | 30.44 | 30.04 | 30.82 | 46.32 |
Diluted EPS Before Non-Recurring Items | -0.81 | -1.08 | -0.58 | -0.36 | -0.68 |
Diluted Net EPS (GAAP) | -0.81 | -1.08 | -0.58 | -0.36 | 14.44 |
Fiscal Year end for XBiotech Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 10.86 | 8.58 | 8.52 | 13.26 | 7.15 |
Income After SG&A, R&D, and Dept/Amort Expenses | -10.86 | -8.58 | -8.52 | -13.26 | -7.15 |
Non-Operating Income | 0.88 | 3.85 | 1.46 | 4.59 | 3.29 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -9.98 | -4.73 | -7.06 | -8.67 | -3.85 |
Income Taxes | 0.03 | -0.10 | 0.31 | 0.07 | -0.04 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -10.00 | -4.63 | -7.36 | -8.74 | -3.82 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -10.00 | -4.63 | -7.36 | -8.74 | -3.82 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | 30.44 | 28.97 | 30.44 | 30.44 | 30.44 |
Diluted EPS Before Non-Recurring Items | -0.33 | -0.16 | -0.24 | -0.29 | -0.13 |
Diluted Net EPS (GAAP) | -0.33 | -0.15 | -0.24 | -0.29 | -0.13 |